CSIMarket
 
Alpha Tau Medical Ltd   (DRTS)
Other Ticker:  
 
 
Price: $2.8800 $0.03 1.046%
Day's High: $2.96 Week Perf: -0.69 %
Day's Low: $ 2.86 30 Day Perf: -10.28 %
Volume (M): 15 52 Wk High: $ 4.80
Volume (M$): $ 44 52 Wk Avg: $3.38
Open: $2.86 52 Wk Low: $2.70



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 29
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 6

Alpha Tau Medical Ltd
Alpha Tau Medical Ltd is a medical technology company that specializes in cancer treatment using a breakthrough technology called Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). This innovative therapy involves the use of alpha-emitng radioactive atoms to target and destroy cancer cells, while sparing healthy surrounding tissues. Alpha Tau Medical aims to provide a non-invasive and effective treatment option for various types of solid tumors, including those that are resistant to other therapies. The company is dedicated to improving the lives of cancer patients and making a positive impact in the field of oncology.


   Company Address: Kiryat HaMada St. 5 Jerusalem 9777605
   Company Phone Number: (3) 577-4115   Stock Exchange / Ticker: NASDAQ DRTS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Alpha Tau Medical Ltd

Alpha Tau Medical Ltd Surpasses Earnings Expectations with $35.68 Million Operating Surplus in Q4 2023



The Medical Equipment & Supplies sector is currently in the spotlight as contributors begin to analyze the fourth quarter of 2023 earnings. One significant player in the industry is Alpha Tau Medical Ltd, a renowned developer of alpha radiation cancer therapy. While the company has recently revealed positive interim safety and feasibility data from a pancreatic cancer study, there are several concerns that cast a bearish shadow over their future prospects.
Financial Performance:
Alpha Tau Medical Ltd reported an operating surplus of $35.68 million for the October to December 31, 2023 financial reporting period, surpassing last year's result of $32.136 million. However, it is crucial to note that the company has not specified any revenue yet. This absence of revenue raises questions about their ability to generate sustainable income and casts doubt on the long-term viability of the company.

Product Service News

Breaking Boundaries in Pancreatic Cancer: Alpha DaRT Treatment Unleashes Hope in Interim Results

Published Tue, Nov 28 2023 1:30 PM UTC


Introduction
Alpha Tau Medical, a leading global developer of alpha radiation cancer therapy, has recently announced highly promising interim results from their safety and feasibility trial for the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) treatment in advanced pancreatic cancer patients. The interim data for this innovative therapy demonstrate success...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com